Gonadorelin

Gonadorelin is a synthetic gonadotropin-releasing hormone used to stimulate the pituitary release of LH and FSH for HPG-axis research and endocrine modulation. While community users often report running 1 mg daily, clinician-tier protocols utilize significantly lower doses ranging from 5 µg to 200 µg daily via subcutaneous injection. Readers should note that all human use is off-label or compounded, and the evidence base for exploratory indications remains thin, with most research lacking published results. Injection-site reactions, histamine responses, and fluid retention have not been consistent themes in user reports.

Half-life~2 min

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsno dataAnecdotalEfficacyAnecdotalSideEffectsPrice2.21.72.83.12.0

Measured on 5 of 6 axes

Research Evidence

Evidence shape

Gonadorelin possesses low-tier human evidence, primarily consisting of diagnostic and mechanistic studies rather than clinical treatment trials. While twenty-six published studies exist, the research remains exploratory, with no completed clinical trials to establish efficacy for its various indications. Current research activity is limited to two active or recruiting trials, and the majority of mapped indications rely on thin data or preclinical models. This lack of completed, large-scale human trials means the clinical utility of the peptide remains unverified by standard research benchmarks.

Depthhow much
2 registered trials
1 completed · 1 with posted results · 1 recruiting / active · combined n=62
Breadthhow many areas
5 indications mapped
4 thin / exploratory · 1 animal-only · 2 single-trial long-tail
Qualityhow rigorous
Highest tier: trial
1 linked publication on registered trials
Breadth and depth34 rows captured
Human
direct clinical signal
28
Animal
translational support
4
In vitro
mechanistic support
2
HighMediumLow

Anecdotal efficacy

Gonadorelin side effects

Clinical research side effects

Grouped from 8 published human studies — weighted by study count, not incidence (the papers report no rates).

Anecdotal side effects

Price

Full buying guide →
1
High Purity Peptides
Hong Kong
20 mg×10
$30.00
$1.5/mg
2
HKRoids
Hong Kong
20 mg×10
$40.00
$2/mg
3
Chimera Peptides
CN
20 mg×10
$79.00
$3.95/mg
4
Liberty Peptides
USA
10 mg
$64.00
$6.4/mg
5
Paramount Peptides
unknown
10 mg
$65.45
$6.54/mg
6
Mt Meipept
US
10 mg
$72.00
$7.2/mg

price offers can be sorted by column · 4 out-of-stock offers not shown

1-6 of 39

Gonadorelin dosing & protocol

How Gonadorelin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 11
Typical dose
1.2 mg
typical
0
500 µg
1 mg
1.5 mg
across 1 dosed source · darker = more agree
Frequency
daily
Route
subQ

In the research trials reviewed, gonadorelin was given at a typical dose of 1.2 mg subcutaneously each day, with the dose range consistently reported as 1.2–1.2 mg and no cycling protocol described.

11 sources
Clinician practice
Doctor & published-protocol guidance · n = 2
Typical dose
5 µg5 µg – 200 µg
typical
0
500 µg
1 mg
1.5 mg
distribution of 4 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
subQ

Clinician practice reports Gonadorelin dosing typically around 5 mcg subcutaneously each day, with observed ranges from 5 mcg to 200 mcg daily, and no specific cycling pattern is noted.

2 sources
Anecdotal
Community-reported real-world use · n = 1
Typical dose
1 mg
typical
0
500 µg
1 mg
1.5 mg
single reported dose
Frequency
unspecified
Route
subQ

Users typically report a 1 mg dose of gonadorelin, split into two administrations, given subcutaneously; no consistent frequency or cycling pattern was noted in the available reports.

1 source

Related peptides

PT-141Kisspeptin-10HCGTriptorelinOxytocin